Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Industry Hauls Post-Brexit UK Over The Coals

IP Protections & Access To Innovation Seen As Weak Points

Executive Summary

PhRMA wants the UK to be placed on the US Trade Representative’s “Watch List” over issues such as the supplementary protection certificate waiver and delays in access to new drugs caused by “overlapping” cost-containment measures.

You may also be interested in...



US Industry Slams Russia And Turkey For IP And Market Access 'Failures'

Compulsory licensing in Russia, domestic production measures in Turkey, and clinical trial requirements for Germany’s pricing and reimbursement process come under fire in PhRMA's “Special 301” report to the US Trade Representative.

UK Industry Concerned Over 26% Sales Tax Prediction For 2023

The UK government says it remains committed to the principle of co-creating a positive environment for the development of commercial medicines but there is concern in the life sciences sector over the revelation that companies could be made to pay as much as 26% of their sales in 2023 in rebates to the government.

EU Actions ‘Will Weaken IP And Undermine Innovation’

In its 2022 “Special 301” submission, US pharmaceutical industry group PhRMA says that EU data protections and other incentives for innovative R&D are under threat, echoing concerns already expressed by European industry bodies.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel